251 related articles for article (PubMed ID: 19396785)
1. Incidence of hyperemia associated with bimatoprost treatment in naïve subjects and in subjects previously treated with latanoprost.
Kurtz S; Mann O
Eur J Ophthalmol; 2009; 19(3):400-3. PubMed ID: 19396785
[TBL] [Abstract][Full Text] [Related]
2. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Parrish RK; Palmberg P; Sheu WP;
Am J Ophthalmol; 2003 May; 135(5):688-703. PubMed ID: 12719078
[TBL] [Abstract][Full Text] [Related]
3. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
4. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
Konstas AG; Katsimbris JM; Lallos N; Boukaras GP; Jenkins JN; Stewart WC
Ophthalmology; 2005 Feb; 112(2):262-6. PubMed ID: 15691561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
DuBiner H; Cooke D; Dirks M; Stewart WC; VanDenburgh AM; Felix C
Surv Ophthalmol; 2001 May; 45 Suppl 4():S353-60. PubMed ID: 11434938
[TBL] [Abstract][Full Text] [Related]
6. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost.
Gandolfi SA; Cimino L
Ophthalmology; 2003 Mar; 110(3):609-14. PubMed ID: 12623831
[TBL] [Abstract][Full Text] [Related]
7. A randomized, prospective study of bimatoprost 0.01% or travoprost/timolol in patients previously treated with latanoprost and timolol to reduce intraocular pressure.
Nixon DR
J Ocul Pharmacol Ther; 2013 Dec; 29(10):876-81. PubMed ID: 24070367
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
9. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.
Noecker RS; Dirks MS; Choplin NT; Bernstein P; Batoosingh AL; Whitcup SM;
Am J Ophthalmol; 2003 Jan; 135(1):55-63. PubMed ID: 12504698
[TBL] [Abstract][Full Text] [Related]
10. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study.
Casson RJ; Liu L; Graham SL; Morgan WH; Grigg JR; Galanopoulos A; Crawford A; House PH
J Glaucoma; 2009; 18(8):582-8. PubMed ID: 19826386
[TBL] [Abstract][Full Text] [Related]
12. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost.
Stewart WC; Kolker AE; Stewart JA; Leech J; Jackson AL
Am J Ophthalmol; 2003 Mar; 135(3):314-20. PubMed ID: 12614748
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
[TBL] [Abstract][Full Text] [Related]
14. Bimatoprost 0.01% in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting.
Park KH; Simonyi S; Kim CY; Sohn YH; Kook MS
BMC Ophthalmol; 2014 Dec; 14():160. PubMed ID: 25519810
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial.
Koz OG; Ozsoy A; Yarangumeli A; Kose SK; Kural G
Acta Ophthalmol Scand; 2007 Dec; 85(8):838-43. PubMed ID: 17680841
[TBL] [Abstract][Full Text] [Related]
16. Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.
Wang K; Xu L; Yuan Z; Yao K; Zhao J; Xu L; Fang A; Zhang M; Wu L; Ji J; Hou J; Liu Q; Sun X
BMC Ophthalmol; 2014 Feb; 14():21. PubMed ID: 24568617
[TBL] [Abstract][Full Text] [Related]
17. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials.
Honrubia F; García-Sánchez J; Polo V; de la Casa JM; Soto J
Br J Ophthalmol; 2009 Mar; 93(3):316-21. PubMed ID: 19019922
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
Martinez A; Sanchez M
Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study.
Kammer JA; Katzman B; Ackerman SL; Hollander DA
Br J Ophthalmol; 2010 Jan; 94(1):74-9. PubMed ID: 19726422
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucoma.
Sato S; Hirooka K; Baba T; Mizote M; Fujimura T; Tenkumo K; Ueda H; Shiraga F
J Ocul Pharmacol Ther; 2011 Oct; 27(5):499-502. PubMed ID: 21790301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
